• Northwest Biotherapeutics entered a $5.51 million Commercial Loan Agreement and Note with Streeterville Capital on October 26, 2026.
• The loan matures in 22 months, carries 8% annual interest and includes a 10% original issue discount.
• No repayments are required for eight months; 14 equal monthly principal installments begin June 26, 2027.
• Each installment requires 110% of the pro rata principal amount, plus accrued interest.
• Proceeds will fund ongoing business operations; optional prepayment at any time carries a 10% charge.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-120669), on October 30, 2026, and is solely responsible for the information contained therein.